These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 27236770)
1. Are the Formulas Used to Estimate Renal Function Adequate for Patients Treated With Cisplatin-Based Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Carcinoma? Niwa N; Kikuchi E; Masashi M; Tanaka N; Nishiyama T; Miyajima A; Saito S; Oya M Clin Genitourin Cancer; 2016 Oct; 14(5):e501-e507. PubMed ID: 27236770 [TBL] [Abstract][Full Text] [Related]
2. Prediction of renal function after nephroureterectomy in patients with upper tract urothelial carcinoma. Hashimoto T; Ohno Y; Nakashima J; Gondo T; Nakagami Y; Namiki K; Horiguchi Y; Yoshioka K; Ohori M; Tachibana M Jpn J Clin Oncol; 2015 Nov; 45(11):1064-8. PubMed ID: 26355160 [TBL] [Abstract][Full Text] [Related]
3. Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma. Kaag M; Trost L; Thompson RH; Favaretto R; Elliott V; Shariat SF; Maschino A; Vertosick E; Raman JD; Dalbagni G BJU Int; 2014 Nov; 114(5):674-9. PubMed ID: 24314050 [TBL] [Abstract][Full Text] [Related]
4. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. Xylinas E; Rink M; Margulis V; Clozel T; Lee RK; Comploj E; Novara G; Raman JD; Lotan Y; Weizer A; Roupret M; Pycha A; Scherr DS; Seitz C; Ficarra V; Trinh QD; Karakiewicz PI; Montorsi F; Zerbib M; Shariat SF; BJU Int; 2013 Aug; 112(4):453-61. PubMed ID: 23464979 [TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome. Yafi FA; Tanguay S; Rendon R; Jacobsen N; Fairey A; Izawa J; Kapoor A; Black P; Lacombe L; Chin J; So A; Lattouf JB; Bell D; Fradet Y; Saad F; Matsumoto E; Drachenberg D; Cagiannos I; Kassouf W Urol Oncol; 2014 Jan; 32(1):31.e17-24. PubMed ID: 23428535 [TBL] [Abstract][Full Text] [Related]
6. [Impact of first-line chemotherapy on renal function in patients with advanced upper tract urothelial carcinoma]. Li X; Sheng XN; Chi ZH; Cui CL; Si L; Mao LL; Tang BX; Lian B; Wang X; Yan XQ; Li SM; Bai X; Zhou L; Kong Y; Dai J; Guo J Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(32):2574-2578. PubMed ID: 30220142 [No Abstract] [Full Text] [Related]
7. Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract. Cho KS; Joung JY; Seo HK; Cho IC; Chung HS; Chung J; Lee KH Cancer Chemother Pharmacol; 2011 Apr; 67(4):769-74. PubMed ID: 20532510 [TBL] [Abstract][Full Text] [Related]
8. High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy. Raman JD; Lin YK; Kaag M; Atkinson T; Crispen P; Wille M; Smith N; Hockenberry M; Guzzo T; Peyronnet B; Bensalah K; Simhan J; Kutikov A; Cha E; Herman M; Scherr D; Shariat SF; Boorjian SA Urol Oncol; 2014 Jan; 32(1):47.e9-14. PubMed ID: 24140248 [TBL] [Abstract][Full Text] [Related]
9. The Efficacy of Postoperative Adjuvant Chemotherapy for Patients with pT3N0M0 Upper Tract Urothelial Carcinoma. Huang YC; Chen MF; Shi CS; Shindel AW; Huang CE; Pang ST; Chuang CK; Chen CS; Chang YH; Lin WY; Ho DR; Chin CC; Kuo YH; Wu CF J Urol; 2015 Aug; 194(2):323-9. PubMed ID: 25796114 [TBL] [Abstract][Full Text] [Related]
10. The renal safety and efficacy of combined gemcitabine plus cisplatin and gemcitabine plus carboplatin chemotherapy in Chinese patients with a solitary kidney after nephroureterectomy. Sun P; Xue C; Li LR; Shao C; An X; Thomas R; Yang W; Deng YF; Jiang WQ; Shi YX Cancer Chemother Pharmacol; 2017 Jul; 80(1):37-44. PubMed ID: 28534209 [TBL] [Abstract][Full Text] [Related]
11. [Clinical studies of chemotherapy for patients with a solitary kidney after nephroureterectomy for advanced upper urothelial transitional cell carcinoma]. Tsujimura A; Takayama H; Tsukikawa M; Imazu T; Sugao H; Takaha M Hinyokika Kiyo; 1995 Mar; 41(3):183-9. PubMed ID: 7741070 [TBL] [Abstract][Full Text] [Related]
12. Role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma and the prognostic significance of C-reactive protein: A multi-institutional, retrospective study. Fujita K; Inamoto T; Yamamoto Y; Tanigawa G; Nakayama M; Mori N; Tsujihata M; Azuma H; Nonomura N; Uemura M Int J Urol; 2015 Nov; 22(11):1006-12. PubMed ID: 26153093 [TBL] [Abstract][Full Text] [Related]
13. Performance of formulas for estimating glomerular filtration rate in Indigenous Australians with and without Type 2 diabetes: the eGFR Study. Maple-Brown LJ; Ekinci EI; Hughes JT; Chatfield M; Lawton PD; Jones GR; Ellis AG; Sinha A; Cass A; Hoy WE; O'Dea K; Jerums G; MacIsaac RJ; Diabet Med; 2014 Jul; 31(7):829-38. PubMed ID: 24598003 [TBL] [Abstract][Full Text] [Related]
14. Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy. Shao IH; Lin YH; Hou CP; Juang HH; Chen CL; Chang PL; Tsui KH Drug Des Devel Ther; 2014; 8():1985-90. PubMed ID: 25364228 [TBL] [Abstract][Full Text] [Related]
15. The effect of contralateral kidney volume on renal function after radical nephroureterectomy: Implications for eligibility for neoadjuvant chemotherapy for upper tract urothelial cancer. Song W; Sung HH; Han DH; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Jeon HG Urol Oncol; 2017 Mar; 35(3):114.e1-114.e7. PubMed ID: 27908680 [TBL] [Abstract][Full Text] [Related]
16. Predictive ability of renal cortex enhancement in dynamic computed tomography for residual renal function after nephroureterectomy: Comparison with Waseda Y; Saito K; Ishikawa Y; Kawano K; Yokoyama M; Ishioka J; Matsuoka Y; Morimoto S; Kihara K; Fujii Y Int J Urol; 2019 Feb; 26(2):266-272. PubMed ID: 30368933 [TBL] [Abstract][Full Text] [Related]
17. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Kaag MG; O'Malley RL; O'Malley P; Godoy G; Chen M; Smaldone MC; Hrebinko RL; Raman JD; Bochner B; Dalbagni G; Stifelman MD; Taneja SS; Huang WC Eur Urol; 2010 Oct; 58(4):581-7. PubMed ID: 20619530 [TBL] [Abstract][Full Text] [Related]
18. New classification of hydronephrosis on 18F-FDG-PET/CT predicts post-operative renal function and muscle-invasive disease in patients with upper urinary tract urothelial carcinoma. Asai S; Fukumoto T; Watanabe R; Koyama K; Sawada Y; Noda T; Miura N; Yanagihara Y; Miyauchi Y; Miyagawa M; Kikugawa T; Saika T Jpn J Clin Oncol; 2018 Nov; 48(11):1022-1027. PubMed ID: 30252103 [TBL] [Abstract][Full Text] [Related]
19. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Dash A; Galsky MD; Vickers AJ; Serio AM; Koppie TM; Dalbagni G; Bochner BH Cancer; 2006 Aug; 107(3):506-13. PubMed ID: 16773629 [TBL] [Abstract][Full Text] [Related]
20. A comparison of nephrotoxicity between patients with a solitary-functioning kidney and those with bilateral-functioning kidneys in cisplatin-based chemotherapy for advanced urothelial carcinoma: a Japanese retrospective multi-institutional study. Inoue T; Miyazaki J; Ichioka D; Narita S; Kageyama S; Sugimoto M; Mitsuzuka K; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Matsui Y; Fujie K; Habuchi T; Nishiyama H BMC Cancer; 2018 Mar; 18(1):290. PubMed ID: 29540229 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]